Marina Konorty

EVP, Research & Development & Technical Operations at UroGen Pharma

Marina is a highly specialized leader in pivotal areas of our company, having joined UroGen as Chief Chemist in 2011.

In her role as Chief Chemist, Marina was responsible for the development of the RTGelTM reverse-thermal hydrogel technology platform, including optimization of its delivery properties and verifying its suitability as a drug carrier in humans.

In her current role, Marina heads development of the manufacturing processes and specifications associated with RTGel-formulated drug products for the UroGen clinical development pipeline.

Prior to UroGen, Marina served as Project Manager at TransPharma Medical, a medical device, and drug delivery company.

A published author with multiple patents, Marina holds a Ph.D. in organic chemistry from the Weizmann Institute of Science and a master of science and bachelor of science in chemical engineering from the Technion Institute of Technology.

Location

Ra'anana, Israel

Links


Org chart


Teams


Offices

This person is not in any offices


UroGen Pharma

UroGen Pharma is a biopharmaceutical company that builds novel solutions to revolutionize the way specialty cancers and urologic diseases are treated – because patients deserve better options.


Industries

Employees

51-200

Links